Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001213900-25-084258
Filing Date
2025-09-04
Accepted
2025-09-04 06:34:13
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 6569
  Complete submission text file 0001213900-25-084258.txt   8485
Mailing Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301
Business Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301 (346) 355-4099
Alaunos Therapeutics, Inc. (Subject) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-79364 | Film No.: 251291850
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1050 CROWN POINTE PARKWAY SUITE 500 ATLANTA GA 30338
Business Address 1050 CROWN POINTE PARKWAY SUITE 500 ATLANTA GA 30338 404-996-2817
Strategic EP, LLC (Filed by) CIK: 0002081874 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G